News

Patients on the study drug demonstrated improvements in several different exploratory cardiac end points, including NT-proBNP and echocardiographic parameters relative to placebo.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed new untapped ways seizure apps could help patients with epilepsy. [WATCH TIME: 2 minutes]

The senior VP of clinical research and deputy chief clinical officer of the neurology business group at Eisai spoke to the recent first enrollment in the Tau NexGen study of the investigational antimicrotubule binding region tau antibody, E2814.

The cognitive neurologist at the University of California San Francisco provided insight on how she’s taken a cognitive neurology approach to the COVID-19 pandemic, and how her background in HIV influenced her recent research. [WATCH TIME: 5 minutes]

Here's what is coming soon to NeurologyLive®.

The clinical hold comes 2 days after an announcement from Denali Therapeutics detailing a partnership with Takeda Pharmaceutical Company to codevelop and cocommercialize the treatment.

The trial will also include another investiartional Eisai agent, the antiamyloid therapy lecanemab, as the background study drug to evaluate the true effect of E2814 has on patients with dominantly inherited Alzheimer disease.

The director of the Pediatric Headache Program at CHOP commented on the need to treat migraine early to avoid secondary effects and decrease the odds of long-term disability. [WATCH TIME: 3 minutes]

In a Health Union survey of more than 400 patients, those with focal seizures were more likely to say they’ve experienced discrimination, isolation, and reduced productivity at work compared with those without.

Years of mounting data has led the National Headache Foundation to release recommendations on how patients and clinicians come to the right decisions on migraine therapy.

Dubbed COVID-DoC, the prospective study is the largest of its kind to date and provides initial data on the prognosis and pathophysiology of the condition in a group of patients at Massachusetts General Hospital.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

Discussing the need to identify an effective first-line treatment, the director of the Pediatric Headache Program at CHOP further discussed treatment adherence in this patient population. [WATCH TIME: 5 minutes]

The risk of 5-year ipsilateral recurrent stroke was 14.3% for those with Symptomatic Carotid Atheroma Inflammation Lumen-Stenosis scores of at least 3 compared with 2.6% for those with low-risk category scores.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center gave her expert opinion on whether seizure app usage has increased during the COVID-19 pandemic and why there remains a need for further data collections. [WATCH TIME: 2 minutes]

Hypoperfusion index was able to estimate the rate of core progression in patients with stroke who had otherwise unclassified progression by reperfusion trial core time criteria.

The study of 251 hospitalized patients with COVID-19 found that biomarkers were elevated to levels that were similar to—or even higher than—those observed in patients with Alzheimer disease.

After a post hoc analysis revealed promising results in a subgroup of younger adults with less disease burden, Ionis has announced that Roche will develop a new phase 2 trial.

The director of the Pediatric Headache Program at CHOP commented on the available therapies for children with migraine, as well as future developments. [WATCH TIME: 4 minutes]

The director of the Pediatric Headache Program at CHOP broke down the treatment of pediatric migraine into 3 different pieces: lifestyle habits, acute treatment, and preventive therapies. [WATCH TIME: 5 minutes]

Yumanity Therapeutics announced the hold, which was in response to an investigational new drug application submitted to the FDA in December 2021.

The trial is a twin of ENSURE-1, which began in November 2021, and is supported by positive clinical data from the phase 2 EMPhASIS trial.

Zhittya Genesis Medicine announced the trial to evaluate its biological drug, FGF-1, which is administered via an intranasal delivery device, in a cohort of individuals with mild to moderate ALS.

The director of the CHOP Pediatric Headache Program commented on the commonality of migraine in children and the need to improve diagnostic practices. [WATCH TIME: 4 minutes]

In cases with reported behavioral variant AD, investigators observed AD-like pattern with relative frontal sparing and a relatively more behavioral variant frontotemporal dementia-like pattern with both posterior and anterior involvement.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center detailed the benefits seizure apps provide for patients with epilepsy, as well as the barriers that limit them. [WATCH TIME: 3 minutes]

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided an inside look at the ways MR fingerprinting can provide real-time clinical benefit for physicians and patient care.

Investigators suggest that sex-specific strategies should be invoked to reduce the amount of early stroke deaths after observations suggest that female sex is linked to lower risk of stroke-related events.

David Fischer, MD, neurocritical care fellow at Massachusetts General Hospital and Brigham and Women’s Hospital, outlined findings from a recent study that evaluated hospitalized patients with COVID-19 who were not regaining consciousness.